Effects of pituitary hormones on the prostate

Prostate

Volumn 38, Issue 2, 1999, Pages 159-165

  Reiter, Eric ^a,b   Hennuy, Benoit ^b   Bruyninx, Marc ^b   Cornet, Anne ^b   Klug, Marc ^b   McNamara, Michael ^b   Closset, Jean ^b   Hennen, Georges ^b  

^a UMR85 PHYSIOLOGIE DE LA REPRODUCTION ET DES COMPORTEMENTS   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Growth hormone; Luteinizing hormone; Prolactin; Prostate

Indexed keywords

ANDROGEN; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HYPOPHYSIS HORMONE; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; PROLACTIN; SOMATOMEDIN C;

ARTICLE; CARCINOGENESIS; ENZYME INDUCTION; GENETIC TRANSCRIPTION; HORMONE ACTION; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY;

ANIMALS; GROWTH HORMONE; HUMANS; LUTEINIZING HORMONE; MICE; PITUITARY GLAND; PITUITARY HORMONES, ANTERIOR; PROLACTIN; RATS;

EID: 0032951354     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990201)38:2<159::AID-PROS10>3.0.CO;2-5     Document Type: Article

References (69)

1. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-362.
2. Isaacs JT. Antagonistic effect of androgens on prostatic cell death. Prostate 1984;5:545-557.
3. Schröder FH. Endocrine therapy for prostate cancer: recent developments and current status. Br J Urol 1993;71:633-640.
4. Wilding G. Endocrine control of prostate cancer. Cancer Surv 1995;23:43-62.
5. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab 1983;57:71-77.
6. Nankin HR, Calkins JH. Decreased bioavailable testosterone in aging normal and impotent men. J Clin Endocrinol Metab 1986; 63:1418-1420.
7. Story MT. Polypeptide modulators of prostatic growth and development. Cancer Surv 1991;11:123-146.
8. Steiner MS. Role of peptide growth factors in the prostate: a review. Urology 1993;42:99-110.
9. Sinowatz F, Amselgruber W, Pendl J, Kölle S, Neumüller C, Boos G. Effects of hormones on the prostate in adult and aging men and animals. Microsc Res Techn 1995;30:282-292.
10. Cunha GR, Sekkingstad M, Meloy BA. Heterospecific induction of prostatic development in tissue recombinants prepared with mouse, rat, rabbit and human tissues. Differentiation 1983;24: 174-180.
11. Cunha GR, Chung LWK, Shannon JM, Taguchi O, Fujii H. Hormone induced morphogenesis and growth: role of mesenchymal epithelial interactions. Recent Prog Horm Res 1983;39:559-598.
12. Hunggins C, Russell PS. Quantitative effects of hypophysectomy on testis and prostate of dogs. Endocrinology 1946;39:1-7.
13. Grayhack JT, Bunce PL, Kearns JW, Scoot WW. Influence of the pituitary on prostatic response to androgen in the rat. Bull Johns Hopkins Hosp 1955;96:154-321.
14. Brendler H. Adrenalectomy and hypophysectomy for prostate cancer. Urology 1973;2:99-102.
15. Grayhack JT. Pituitary factors influencing growth of the prostate. NCI Monogr 1963;12:189-199.
16. Negro-Vilar A, Saad WA, McCann SM. Evidence for a role of prolactin in prostate and seminal vesicle growth in immature animals. Endocrinology 1977;100:729-737.
17. Costello LC, Franklin RB. Effect of prolactin on the prostate. Prostate 1994;24:162-166.
18. Smith C, Assimos D, Lee C, Grayhack JT. Metabolic action of prolactin in regressing prostate: independent of androgen action. Prostate 1985;6:49-59.
19. Prins GS, Lee C. Biphasic response of the rat lateral prostate to increasing levels of serum prolactin. Biol Reprod 1983;29:938-945.
20. Dombrowicz D, Sente B, Closset J, Hennen G. Dose-dependent effects of human prolactin on the immature hypophysectomized rat testis. Endocrinology 1992;130:695-700.
21. Aragona C, Friesen HG. Specific prolactin binding site in the prostate and testis of rats. Endocrinology 1975;97:677-684.
22. Barkey RJ, Shani J, Amit T, Barzilai D. Specific binding of prolactin to seminal vesicle, prostate, and testicular homogenates of immature, mature and aged rats. J Endocrinol 1977;74:163-173.
23. Thompson SA, Johnson MP, Brooks CL. Biochemical and immunohistochemical characterization of prolactin binding in rat ventral, lateral, and dorsal prostate lobes. Prostate 1982;3:45-58.
24. Yamanaka H, Kirdani RY, Saroff J, Murphy GP, Sandberg AA. Effects of testosterone and prolactin on rat prostatic weight, 5α-reductase and arginase. Am J Physiol 1975;229:1102-1110.
25. Baraneo JLS, Legnani B, Chiauzzi VA, Bertini LM, Suescun MO, Calvo JC, Charreau EH, Calandra RS. Effects of prolactin on androgen metabolism in androgen target tissues of immature rats. Endocrinology 1982;109:2188-2195.
26. Jones R, Riding PR, Parker MG. Effect of prolactin or testosterone induced growth and protein synthesis in rat accessory sex glands. J Endocrinol 1983;96:407-416.
27. Prins GS. Prolactin influence on cytosol and nuclear androgen receptors in the ventral, dorsal and lateral lobes of the rat prostate. Endocrinology 1987;120:1457-1464.
28. Reiter E, Bonnet P, Sente B, Dombrowicz D, De Leval J, Closset J, Hennen G. Growth hormone prolactin stimulates androgen receptor, insulin-like growth factor-I and IGF-I receptor levels in the prostate of immature rats. Mol Cell Endocrinol 1992;88:77-87.
29. Nevalainen MT, Valve EM, Mäkelä SI, Bläuer M, Tuohimaa PJ, Härkönen PL. Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture. Endocrinology 1991;129: 612-622.
30. Franklin RB, Costello LC. Prolactin stimulates transcription of mitochondrial aspartate aminotransferase of prostate epithelial cells. Mol Cell Endocrinol 1992;90:27-32.
31. Rui H, Purvis K,. Hormonal control of prostate function. Scand J Urol Nephrol [Suppl] 1988;107:32-38.
32. Reiter E, Lardinois S, Klug M, Sente B, Hennuy B, Bruyninx M, Closset J, Hennen G. Androgen-independent effects of prolactin on the different lobes of the rat prostate. Mol Cell Endocrinol 1995;112:113-122.
33. Wakao H, Gouilleux F, Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J 1994; 13:2182-2191.
34. Tangbanluekal L, Robinette CL. Prolactin mediates estradiol-induced inflammation in the lateral prostate of Wistar rats. Endocrinology 1993;132:2407-2416.
35. Lane KE, Leav I, Ziar J, Bridges RS, Rand WM, Ho S-M. Suppression of testosterone and estradiol-17β-induced dysplasia in the dorsolateral prostate of Noble rats by bromocriptin. Carcinogenesis 1997;18:1505-1510.
36. Bosland MC, Ford H, Horton L. Induction of high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estadiol-17β or DES. Carcinogenesis 1995;16:1311-1317.
37. Wennbo H, Kindblom J, Isaksson OGP, Törnell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 1997;138:4410-4415.
38. Vekemans M, Robyn C. Influence of age on serum prolactin levels in women and men. Br Med J [Clin Res] 1975;4:738-739.
39. Hammond GL, Kontturi M, Maattala P, Puukka M, Vihko R. Serum FSH, LH and prolactin in normal males and patients with prostatic diseases. Clin Endocrinol (Oxf) 1977;7:129-135.
40. Saroff J, Kirdani RY, Chu M, Wajsan Z, Murphy GP. Measurements of prolactin and androgens in patients with prostatic diseases. Oncology 1980;37:46-52.
41. Odoma S, Chisholm GD, Nicol K, Habib FK. Evidence for the association between blood prolactin and androgen receptor in BPH. J Urol 1985;133:717-720.
42. Harper ME, Peeling WB, Cowley T, Brownsey BG, Philips MEA, Groom G, Fahmy DR, Griffiths K. Plasma steroid and protein hormone concentration in patients with prostatic carcinoma, before and during estrogen therapy. Acta Endocrinol (Copenh) 1976;81:409-426.
43. Nevalainen MT, Valve EM, Ingelton PM, Nuemi M, Martikainen PM, Härkönen PL. Prolactin and prolactin receptors are expressed and functioning in the human prostate. J Clin Invest 1997;99:618-627.
44. Nevalainen MT, Valve EM, Ahonen T, Yagi A, Paranko J, Härkönen PL. Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture. FASEB J 1997;11:1297-1307.
45. Lobie PE, Breipohl W, Garcia-Aragon J, Water MJ. Cellular localization of the growth hormone receptor/binding protein in the male and female reproductive systems. Endocrinology 1990; 126:2214-2221.
46. Reiter E, Kecha O, Hennuy B, Lardinois S, Klug M, Bruyninx M, Closset J, Hennen G. Growth hormone directly affects the function of the different lobes of the rat prostate. Endocrinology 1995;136:3338-3345.
47. Ghosh PK, Bartke A. Effects of the expression of bovine growth hormone on the testes and male accessory reproductive glands in transgenic mice. Transgenic Res 1993;2:79-83.
48. Nguyen AP, Chandorkak A, Gupta C. The role of growth hormone in fetal mouse reproductive tract differentiation. Endocrinology 1996;137:3659-3666.
49. Jungwirth A, Schally AV, Pinski J, Halmos G, Groot K, Armatis P, Vadillo-Buenfil M. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer 1997;75:1585-1592.
50. McFarland KC, Sprengel R, Phillips HS, Kölher M, Rosemblit N, Nikolics K, Segaloff D, Seeburg PH. Lutropin-choriogonadotropin receptor: an unusual member of G protein-coupled receptor family. Science 1989;245:494-499.
51. Loosfelt H, Misrahi M, Atger M, Salesse R, Vu Haï-Luu Thi MT, Jolivet A, Guiochon-Mantel A, Sar S, Jallal B, Granier J, Milgrom E. Cloning and sequencing of porcine LH-hCG receptor cDNA; variants lacking transmembrane domain. Science 1989;245:525-528.
52. Rao CV. The beginning of a new era in reproductive biology and medicine: expression of low levels of functional luteinizing hormone/human chorionic gonadotropin receptors in non gonadal tissues. J Physiol Pharmacol 1996;47:41-53.
53. Reiter E, McNamara M, Closset J, Hennen G. Expression and functionality of luteinizing hormone/chorionic gonadotropin receptor in the rat prostate. Endocrinology 1995;136:917-923.
54. Roche PC, Ryan RJ. The LH/hCG receptor. In Ascoli M, editor. Luteinizing hormone action and receptors. Florida: CRC Press, Inc.; 1985. p 17-56.
55. Rosemblit N, Ascoli M, Segaloff DL. Characterization of an antiserum to the rat luteal luteinizing hormone/chorionic gonadotropin receptor. Endocrinology 1988;123:2284-2290.
56. Tao YX, Lei ZM, Woodworth SH, Rao CV. Novel expression of luteinizing hormone/chorionic gonadotropin receptor gene in rat prostates. Mol Cell Endocrinol 1995;111:9-12.
57. Reiter E, Poncin J, Hennuy B, Bruyninx M, Klug M, Cornet A, Closset J, Hennen G. Luteinizing hormone increases the abundance of various transcripts, independently of the androgens, in the rat prostate. Biochem Biophys Res Common 1997;233:108-112.
58. Tao YX, Bao S, Ackermann DM, Lei ZM, Rao CV. Expression of luteinizing hormone/human chorionic gonadotropin receptor gene in benign prostatic hyperplasia and in prostate carcinomas in humans. Biol Reprod 1997;56:67-72.
59. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 1994;91:11236-11240.
60. Greenberg NM, De Mayo FJ, Scheppard PC, Barrios R, Lebowitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM, Matusik RJ. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8:230-239.
61. Greenberg NM, De Mayo FJ, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-3443.
62. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, Edery M, Brousse N, Babinet C, Binart N, Kelly PA. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 1997;11:167-178.
63. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E, Dorshkind K. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 1997;16: 6926-6935.
64. Colao A, Marzullo P, Ferone D, Spiezia S, Cerbone S, Marinò V, Di Sarno A, Merola B, Lombardi G. Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 1998; 83:775-779.
65. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-566.
66. Baker J, Hardy MP, Zhou J, Bondy C, Lupu F, Bellvé AR, Efstradiatis A. Effects of an Igf1 gene null mutation on mouse reproduction. Mol Endocrinol 1996;10:903-918.
67. Liu J-P, Baker J, Perkins AS, Robertson EJ, Efstradiatis A. Mice carrying null mutations of the genes encoding insulin like growth factor I (Igf-1) and type 1 Igf receptor (Igf1r). Cell 1993; 75:59-72.
68. Acampora D, Mazan S, Tuorto F, Avantaggiato V, Tremblay JJ, Lazzaro D, diCarlo A, Mariano A, Corte G, Macchia V, Drouin J, Brūlet P, Simeone A. Transient dwarfism and hypogonadism in mice lacking Otx1 reveal prepubescent stage-specific control of pituitary levels of GH, FSH and LH. Development 1998;125: 1229-1239.
69. Lee SL, Sadovsky Y, Swirnoff AH, Polish JA, Goda P, Gavrilina G, Milbrandt J. Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1). Science 1996;273:1219-1221.